The Promise of mRNA Vaccines
The Promise of mRNA Vaccines
Long before Moderna and Pfizer’s COVID-19 shots, scientists had been considering the use of genetically encoded vaccines in the fight against infectious diseases, cancer, and more.
The Promise of mRNA Vaccines
The Promise of mRNA Vaccines

Long before Moderna and Pfizer’s COVID-19 shots, scientists had been considering the use of genetically encoded vaccines in the fight against infectious diseases, cancer, and more.

Long before Moderna and Pfizer’s COVID-19 shots, scientists had been considering the use of genetically encoded vaccines in the fight against infectious diseases, cancer, and more.

clinical research
Moderna’s COVID-19 Vaccine 94 Percent Effective: Initial Data
Moderna’s COVID-19 Vaccine 94 Percent Effective: Initial Data
Max Kozlov | Nov 16, 2020
The results mark the second experimental COVID-19 vaccine to show high efficacy, but the study is not complete and the data have not been peer reviewed.
Updated
Pfizer’s COVID-19 Vaccine 90 Percent Effective: Initial Data
Pfizer’s COVID-19 Vaccine 90 Percent Effective: Initial Data
Max Kozlov | Nov 9, 2020
Vaccine experts say the results surpass their expectations, but the study is not complete, and the data have not been peer reviewed.
Scientists Probe Blockers for the Coronavirus Spike Protein
Scientists Probe Blockers for the Coronavirus Spike Protein
Anthony King | Nov 5, 2020
SARS-CoV-2, the virus that causes COVID-19, taps into human proteases such as furin to enter cells. Temporarily inhibiting those enzymes might stymie infection.
Trials Unlikely to Show if COVID-19 Vaccine Prevents Severe Cases
Trials Unlikely to Show if COVID-19 Vaccine Prevents Severe Cases
Max Kozlov | Oct 30, 2020
A vaccine expert explains that such answers likely won’t come until a vaccine has already been approved and administered to millions of people.
New Tracer Gives Clear Picture of Alzheimer’s and Other Dementias
New Tracer Gives Clear Picture of Alzheimer’s and Other Dementias
Ian Le Guillou | Oct 29, 2020
An imaging agent reveals aggregated tau protein in the brain during PET scans and could improve the diagnosis of neurodegenerative diseases, particularly tauopathies.
Eli Lilly Halts Antibody Trial in Hospitalized COVID-19 Patients
Eli Lilly Halts Antibody Trial in Hospitalized COVID-19 Patients
Ashley Yeager | Oct 27, 2020
Recent data show that the drug bamlanivimab, also known as LY-CoV555, does not appear to help those with severe cases of COVID-19, but trials continue for milder cases.
Mexican Senate Votes to Cut Research Funding, Disaster Relief
Mexican Senate Votes to Cut Research Funding, Disaster Relief
Lisa Winter | Oct 22, 2020
Government leaders claim the reductions are necessary to free up assets to deal with COVID-19 and address corruption in research.
A Challenge Trial for COVID-19 Would Not Be the First of Its Kind
A Challenge Trial for COVID-19 Would Not Be the First of Its Kind
Jef Akst | Oct 8, 2020
Although scientists debate the ethics of deliberately infecting volunteers with SARS-CoV-2, plenty of consenting participants have been exposed to all sorts of pathogens in prior trials.
What We Know About Donald Trump’s COVID-19 Treatment Plan
What We Know About Donald Trump’s COVID-19 Treatment Plan
Lisa Winter | Oct 5, 2020
The President was hospitalized on Friday evening and has been receiving an aggressive treatment of experimental and standard drugs.